Lilly, Ascidian link up in RNA exon editing pact

Wednesday, June 3, 2026Gwendolyn WuView original

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

Read the full article on the original site.